首页|Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma

Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma

扫码查看
原文链接
  • NETL
  • NSTL
  • Taylor & Francis
Background: The conventional markers for hepatocellular carcinoma (HCC), a-fetoprotein (AFP) and des-y-carboxy prothrombin (DCP), have several limitations; both have low sensitivity in patients with early-stage HCC; low sensitivity for AFP with HCC after eliminating hepatitis C virus (HCV); low specificity for DCP in patients with non-viral HCC, which is increasing worldwide; low specificity for AFP in patients with liver injury; and low specificity for DCP in patients treated with warfarin. To overcome these issues, the identification of novel biomarkers is an unmet need. Objective: This study aimed to assess the usefulness of serum protein kinase C delta (PKC6) for detecting these HCCs. Methods: PKC5 levels were measured using a sandwich enzyme-linked immunosorbent assay in 363 chronic liver disease (CLD) patients with and without HCC. Results: In both viral and non-viral CLD, PKCδ can detect HCCs with high sensitivity and specificity, particularly in the very early stages. Notably, the value and sensitivity of PKCδ were not modified by HCV elimination status. Liver injury and warfarin administration, which are known to cause false-positive results for conventional markers, did not modify PKCδ levels. Conclusions: PKCδ is an enhanced biomarker for the diagnosis of HCC that compensates for the drawbacks of conventional markers.

HCCPKCbiomarkerearly detectionaetiologypost SVR

Chika Nakagawa、Tsunekazu Oikawa、Kohji Yamada、Akihito Tsubota、Chisato Saeki、Kuniko Katagiri、Naoko Tago、Hiroshi Kamioka、Kaoru Ueda、Koichiro Haruki、Kenei Furukawa、Masanori Nakano、Yuichi Torisu、Toru Ikegami、Kiyotsugu Yoshida、Masayuki Saruta

展开 >

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan

Project Research Units, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan||Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

展开 >

2024

10.1080/1354750X.2024.2312990

Biomarkers

Biomarkers

SCI
ISSN：1354-750X
年,卷(期)：2024.29(1/8)
  • 57